News & Events about Protagonist Therapeutics Inc.
NEWARK, CA / ACCESSWIRE / April 4, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ('Protagonist' or the 'Company') today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per...
Thinking about buying stock in Protagonist Therapeutics, BP, Nio, Axsome Therapeutics, or Petroleo Brasileiro? Thinking about buying stock in Protagonist Therapeutics, BP, Nio, Axsome Therapeutics, or Petroleo Brasileiro? PR Newswire NEW YORK, Oct. 3, 2022 NEW YORK, Oct. 3, 2022 /PRNewswire...
Protagonist Therapeutics (NASDAQ:PTGX Get Rating) was downgraded by StockNews.com from a hold rating to a sell rating in a note issued to investors on Friday. Several other equities analysts have also recently issued reports on the company. Piper Sandler decreased...
Protagonist Therapeutics (NASDAQ:PTGX Get Rating) was downgraded by StockNews.com from a hold rating to a sell rating in a note issued to investors on Friday. Several other equities analysts have also recently issued reports on the company. Piper Sandler decreased their price objective on ...
Northern Trust Corp lessened its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX Get Rating) by 0.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 455,411 shares of the company&#...